Use of bevacizumab in patients with advanced or metastatic disease
Intended for healthcare professionals
CPD Previous    

Use of bevacizumab in patients with advanced or metastatic disease

Carole Farrell Nurse clinician, The Christie NHS Foundation Trust, Manchester

Over the past ten years there has been a rapid increase in new biological (targeted) anti-cancer therapies. This brings challenges for nurses to understand how such drugs work, how they are administered and the implications for patients in terms of potential side effects. Bevacizumab (Avastin®▼) is a monoclonal antibody that targets vascular endothelial growth factor. It is licensed for use in several cancers to treat patients with advanced or metastatic disease including breast, colorectal, renal, non-small cell lung and ovarian. However, there are regional variations in funding arrangements, which nurses should be aware of.

Cancer Nursing Practice. 11, 10, 29-37. doi: 10.7748/cnp2012.


Conflict of interest

The production cost of this article was supported by Roche Products Ltd has checked this article for factual accuracy, with editorial control remaining at all times with the journal

Peer review

This article has been subject to double blind peer review

Want to read more?

Already have access? Log in


3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics

Alternatively, you can purchase access to this article for the next seven days. Buy now

Are you a student? Our student subscription has content especially for you.
Find out more